Pentoxyfilline treatment does not influence the plasma levels of IL-2 and sIL-2R in limited scleroderma patients

BACKGROUND

In this study we investigated whether plasma level of IL-2 or sIL-2R shows the clinical disease status.

MATERIAL AND METHODS

Plasma levels of IL-2 and sIL-2R were measured by ELISA in 23 patients with limited scleroderma (1SSc-acrosclerosis) and compared with 12 healthy women.

RESULTS

Plasma levels of sIL-2R in the group of patients with severe internal organs involvement (3446.1 +/- 1329.7 pg/ml) were significantly higher compared with those with minimal internal organs involvement (1606.4 +/- 507.3 pg/ml). Plasma level of IL-2 in the group of patients with severe internal organs involvement (8.12 +/- 7.77 pg/ml) did not differ much from that of the patients with minimal internal organs involvement (7.42 +/- 9.28 pg/ml). Treatment with pentoxyfilline did not influence the plasma levels of IL-2 and sIL-2R.

CONCLUSIONS

We concluded that elevated plasma levels of IL-2 and sIL-2R are markers of internal organ involvement in scleroderma.

Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): ECG exercise testing--three months follow-up

The ESS-1 study was designed to evaluate the long-term effects of the angiotensin-converting enzyme inhibitor (ACEI) enalapril (10 mg per day) on cardiopulmonary system of patients with systemic sclerosis (SSc). Exercise testing is used not only for estimation of coronary reserve but also physical capacity--the major determinant of quality of life. In each patient included to the ESS-1 study we performed ECG exercise test on treadmill (5 times at intervals of 3 months). The first follow-up was completed by 41 patients (23 patients in enalapril group and 18 in placebo group). The exercise duration in the placebo group was 683 +/- 295 sec and in enalapril group 768 +/- 173 sec. After 3 months of study there were no significant differences in both groups (758 +/- 271 sec and 720 +/- 191 sec respectively). The analysis of ST segment deviation did not provide any significant changes after 3 months of treatment. We conclude that 3 months enalapril treatment did not improve exercise tolerance in patients with systemic sclerosis.

Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): electrocardiographic substudy--three months follow-up

The ESS-1 study was designed to evaluate the long-term effects of enalapril (10 mg per day) on the cardiopulmonary system of patients with systemic sclerosis (SSc). The 3 months follow-up was completed by 41 patients (23 patients in enalapril group and 18 in placebo group). We analysed conventional time domain signal averaged ECG (SAECG). Late potentials were considered to be present in QRS duration (QRS) was > 114 ms or root mean square of last 40 ms (RMS40) was < 20 microV or terminal signal duration under 40 microV (LAS40) was > 38 ms at 40 Hz. At the beginning of study the prevalence of abnormal SAEG parameters was similar in both groups. We observed one abnormal parameter among 13% of patients in enalapril group and 16.7% of patients in placebo group. There were 2 abnormal parameters in 26.1% of patients in enalapril group and 16.7% of patients in placebo group. After three months of treatment we did not find any patient with 2 parameters of late potentials in enalapril group and only 8.7% of patients with one such parameter. In placebo group no substantial improvement was observed.

CONCLUSION

The 3 months enalapril treatment seems to decrease the incidence of late potentials in patients with systemic sclerosis.

Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): pulmonary substudy--effects of three month treatment

The ESS-1 study is designed to evaluate the long-term effects of enalapril on cardiopulmonary system of patients with systemic sclerosis (SSc). During the one year study period 5 visits are scheduled at 3 months intervals. The effect of 3 months treatment with enalapril (10 mg per day) on lung function was studied in 18 patients with SSc (enalapril group) and compared with controls--23 patients with Ssc (placebo group), mean age, SSc duration, gender and % of patients with dcSSc did not differ significantly in both groups. We performed body plethysmography for total airways resistance (Rtot), and static lung volumes (TLC, ITGV and RV), spirometry for FEV1 and FVC and we measured flow parameters (PEF, FEF). We compared initial lung function (first examination) with results after 3 months treatment (second examination) in the enalapril and in the placebo group. Mean values of Rtot, ITGV and RV did not differ significantly in the enalapril group or in the placebo group before and after treatment but FVC, FEV1 and FEF50 were significantly lower in the enalapril group and did not change in the placebo group after three months. We conclude that 3 month treatment with enalapril worsens spirometry of SSc patients. We did not observe any changes in lung functions in the control group in the same three month period.

Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): echocardiographic substudy--three months follow-up

The ESS-1 study was designed to evaluate the long-term effects of the angiotensin converting enzyme inhibitor (ACEI) enalapril (10 mg per day) on the cardio-pulmonary system in patients with scleroderma (SSc). We estimated changes in heart diameters, systolic and diastolic left ventricle function and mean values of pulmonary artery pressure after 3 months treatment. The study group comprise 41 patients with SSc. 18 patients received placebo and 23 ones were given enalapril. After 3 months of treatment we did not observe statistically significant differences in heart diameters and left ventricle systolic function parameters between treated group and placebo. Enalapril therapy did not affect left ventricle diastolic function, nevertheless differences in MVA were almost of statistical significance. Echocardiographic signs of pulmonary hypertension were found in 4 patients.

DNA sequencing with positive and negative errors

The problem addressed in this paper is concerned with DNA sequencing by hybridization. An algorithm is proposed that solves a computational phase of this approach in the presence of both positive and negative errors resulting from the hybridization experiment. No a priori knowledge of the nature and source of these errors is required. An extensive set of computational experiments showed that the algorithm behaves surprisingly well if only positive errors appear. The general case, where positive and negative errors occur, can be also solved satisfactorily for an error rate up to 10%.

[Tuberculosis of the spine: diagnosis and treatment]

The diagnosis and treatment for tuberculosis of the spine, based on own material from years 1992-97 (CMKP Orthopedic Department, Otwock) is presented. One hundred twenty nine patients were treated in these years, 85 of them surgically. The disease appeared usually in 4th, 5th or 6th decade of life, two adjacent vertebral bodies within lower thoracic spine were involved. Contemporary surgical methods as well as approved antibacterial treatment protocols are presented. Twenty-five per cent patients displayed symptoms of neurological impairment, namely paresis or plegia of the lower extremities. Good results of treatment in 85% of cases and only 3% poor results prove efficiency of the management suggested.

Sequential and parallel algorithms for DNA sequencing

MOTIVATION

Reconstruction of the original DNA sequence in the sequencing by the hybridization approach (SBH) requires computational support due to a large number of possible combinations. One can notice a lack of algorithms admitting false-negative data and giving in addition all possible solutions.

RESULTS

In this paper, a new method of sequencing has been proposed. An algorithm based on its idea (for the general case, when some data are missing, like in the real experiment) has been implemented and tested. Authentic DNA sequences have been used for testing. A parallel version of the algorithm has also been implemented and tested. The quality of the reconstruction is satisfactory for the library of oligonucleotides of length between 8 and 12, and 100, 200 and 300 bp long sequences. A way to a further decrease in the computation time is also suggested.

[Our experience with using amrinone in circulatory failure]

A study aimed at evaluating an effect of amrinone of blood circulation dynamics (cardiac output), using impedance ++rheography. The study involved patients with acute, congestive cardiac failure (NYHA III-IV degrees). Cardiac output was measured prior to and 3 and 24 hours following amrinone administration. A favourable effect of a 24-hour i.v. infusion of amrinone on blood circulation dynamics was confirmed. The drug proved to be proarrhythmic.